2012
Multi-Institutional Experience of Ductal Carcinoma In Situ in Black vs White Patients Treated With Breast-Conserving Surgery and Whole Breast Radiation Therapy
Nelson C, Bai H, Neboori H, Takita C, Motwani S, Wright JL, Hobeika G, Haffty BG, Jones T, Goyal S, Moran MS. Multi-Institutional Experience of Ductal Carcinoma In Situ in Black vs White Patients Treated With Breast-Conserving Surgery and Whole Breast Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: e279-e283. PMID: 22672752, DOI: 10.1016/j.ijrobp.2012.03.068.Peer-Reviewed Original ResearchConceptsWhole breast radiation therapyLocal relapse-free survivalRelapse-free survivalBreast-conserving surgeryBreast radiation therapyDCIS patientsRadiation therapyBreast conservationBlack patientsDuctal carcinomaRacial disparitiesUniversity-based cancer centerSignificant overall survival differenceFunction of raceAdjuvant radiation therapyBreast conserving surgeryOverall survival differenceEstrogen receptor statusMulti-institutional cohortMulti-institutional experiencePositive margin rateSignificant racial differencesTreatment delivery parametersPaucity of dataHormonal therapy
1998
Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy
Moran M, Haffty B. Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 353-358. PMID: 9457821, DOI: 10.1016/s0360-3016(97)00573-7.Peer-Reviewed Original ResearchConceptsPercentage of patientsBreast cancer patientsLong-term outcomesConservative surgeryControl groupRadiation therapyHistologic componentsPrimary histologyLobular carcinomaCancer patientsBreast cancerComparable local control ratesDistant disease-free survivalTumor recurrence-free survivalDisease-free survivalLocal control rateRecurrence-free survivalAge of presentationBreast conservation therapyEstrogen receptor statusSignificant differencesReexcision specimenResidual LCISAdjuvant therapyBilateral disease